To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
7 Current news about the topic pioglitazonerss
|You can refine your search further. Select from the filter options on the left to narrow down your results.|
A drug used now to treat Type 2 diabetes may someday help beat breast and ovarian cancers, but not until researchers decode the complex interactions that in some cases help promote tumors, according to Rice University scientists. Rice bioscientist Daniel Carson and alumna Micaela Morgado ...
Analysis of health insurance data suggests preventive effect
Treating people with type 2 diabetes, also known as "age-related diabetes" with antidiabetics reduces their risk for Alzheimer’s and other types of dementia. The risk is most significantly reduced by the drug pioglitazone. Researchers of the German Center for Neurodegenerative Diseases (DZNE) ...
Takeda Pharmaceutical Company Limited announced that an additional indication for “NESINA®” (generic name: Alogliptin), combination therapy with thiazolidinediones for type 2 diabetes, was approved by the Japanese Ministry of Health, Labour and Welfare. NESINA, a dipeptidyl peptidase-IV (DPP-4) ...
Taspoglutide demonstrates superiority in HbA1c change versus placebo as add-on to metformin and pioglitazone
Roche announced that its Phase III study T-emerge 3 met its primary endpoint of change in HbA1c. T-emerge 3 is a study of once weekly taspoglutide versus placebo, as add-on to metformin and pioglitazone. The results of T-emerge 3 showed that taspoglutide demonstrated superiority in HbA1c change ...
The independent business analyst forecasts that the antidiabetics market will be worth $37 billion by 2018 up from $20 billion in 2008. This rapid market expansion presents significant opportunities for pharmaceutical companies who are able to develop new therapies to address the unmet clinical ...
Takeda Canada, Inc. announced that it has reacquired the Canadian commercial rights to ACTOS(R) (pioglitazone HCl), an oral treatment for type 2 diabetes, from Eli Lilly Canada Inc. Takeda, the discoverer of ACTOS, licensed the drug to Lilly as part of a worldwide agreement in 1999. "Reacquiring ...
Takeda Chemical Industries, Ltd. announced that a new research facility at the Oxford Centre for Diabetes, Endocrinology and Metabolism ("OCDEM", Oxford, UK) was opened and named the "Takeda Wing". This has been under construction with Takeda's donation based on the five year partnership starting ...